Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ET-02
- Development stage
- Phase 1
- Lead developer
- Eirion Therapeutics
- Modality
- Small Molecules, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Topical
01
Overview
ET-02 refers to two distinct investigational products identified in clinical development. The first is an allogeneic, "off-the-shelf" chimeric antigen receptor T-cell (CAR-T) therapy developed by EdiGene in collaboration with Immunochina. This therapy, also known as CD19-UCART, targets CD19-positive B-cell malignancies, including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL). It utilizes CRISPR-based gene-editing technology to modify immuno-rejection molecules in T-cells derived from healthy donors, aiming to prevent graft-versus-host disease (GvHD) and host-versus-graft (HvG) rejection. The second ET-02 is a small molecule candidate developed by Eirion Therapeutics for aesthetic indications, specifically targeting androgenic alopecia (hair loss) and hair greying. Eirion's ET-02 is part of a strategic licensing agreement with Shanghai Haohai Biological Technology for the Chinese market.
- Other names
- CD19-UCARTCD-19-UCARTCD 19-UCARTAllogeneic CD19 CAR-T
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on ET-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ET-02.